FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Aurobino Pharma Gets 2nd Warning Letter in 15 months

FDA sends Aurobindo Pharma a Warning Letter over GMP deficiencies cited 8/2021 at its Hyderabad, India-based Unit 1 active pharmaceutical ingredient m...

Human Drugs

Mylan Recalls One Batch of Semglee Insulin

Mylan Pharmaceuticals recalls one batch of its non-interchangeable Semglee (insulin glargine injection), 100 units/ml, 3mL prefilled pens due to the p...

Medical Devices

Sensydia Breakthrough Status for Cardiac Biosensor Monitor

FDA grants Sensydia a breakthrough device designation for its Cardiac Performance System that measures critical cardiac function.

FDA General

FDA Extends Postponement of Inspections Until 2/4

FDA extends until 2/4 a temporary postponement of certain inspection activities due to the spread of the omicron variant.

Human Drugs

FDA Launches REMS Public Dashboard

FDA launches a REMS Public Dashboard to improve data access and transparency.

Medical Devices

Praise, Suggestions for Hearing Aid Rule

Five stakeholders give FDA their recommendations for changes to its proposed rule to establish a regulatory category for OTC hearing aids.

Human Drugs

FDA Met or Exceeded Many FY 2020 User Fee Goals

The latest FDA user fee performance report shows the agency met or exceeded many of its FY 2020 PDUFA and BsUFA goals in several different areas of fo...

Human Drugs

FDA Neuroscience Deputy Bastings Retires, Joins Ionis

Under the cloud of an HHS inspector general probe of alleged FDA coziness in the controversial approval of Biogens Alzheimers therapy Aduhelm, CDER Of...

Human Drugs

FDA Tells Revance to Qualify New Working Cell Bank

FDA tells Revance Therapeutics that to address a recent BLA complete response letter on DaxibotulinumtoxinA for Injection will require qualification o...

Human Drugs

FDA Agrees to New Nomacopan Trial Process

FDA approves a higher-yield manufacturing process for Akari Therapeutics nomacopan for use in two Phase 3 trials.